CLEC12A and Bloom syndrome: The authors of the study believe that, at least in the case of Turkish BS patients, novel targeted therapy drugs specifically “targeting” CLEC12A, CLC, and IFI27 genes/proteins may prove to be of value for therapeutic purposes.